F m Investments LLC Has $3.40 Million Stock Holdings in Spyre Therapeutics, Inc. $SYRE

F m Investments LLC boosted its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 88.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 103,718 shares of the company’s stock after buying an additional 48,825 shares during the quarter. F m Investments LLC’s holdings in Spyre Therapeutics were worth $3,398,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in Spyre Therapeutics by 2,881.7% during the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after purchasing an additional 4,092 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Spyre Therapeutics by 182.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after purchasing an additional 3,725 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Spyre Therapeutics by 61.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after purchasing an additional 1,435 shares during the last quarter. Man Group plc acquired a new position in Spyre Therapeutics during the second quarter valued at approximately $162,000. Finally, Profund Advisors LLC boosted its position in Spyre Therapeutics by 19.7% during the third quarter. Profund Advisors LLC now owns 13,223 shares of the company’s stock valued at $222,000 after purchasing an additional 2,180 shares during the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SYRE shares. BTIG Research raised their price objective on Spyre Therapeutics from $70.00 to $98.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Raymond James Financial started coverage on Spyre Therapeutics in a research report on Monday, April 13th. They issued a “strong-buy” rating and a $80.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised their price objective on Spyre Therapeutics from $55.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Stifel Nicolaus raised their price objective on Spyre Therapeutics from $92.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Wedbush raised their price objective on Spyre Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $89.08.

Spyre Therapeutics Stock Performance

SYRE opened at $75.04 on Friday. Spyre Therapeutics, Inc. has a fifty-two week low of $12.94 and a fifty-two week high of $76.00. The company has a market capitalization of $6.52 billion, a P/E ratio of -36.08 and a beta of 3.12. The stock has a fifty day moving average of $53.47 and a 200-day moving average of $38.67.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). On average, equities research analysts predict that Spyre Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

Insider Transactions at Spyre Therapeutics

In other news, Director Michael Thomas Henderson sold 80,000 shares of Spyre Therapeutics stock in a transaction on Friday, May 8th. The stock was sold at an average price of $74.40, for a total transaction of $5,952,000.00. Following the completion of the sale, the director owned 88,606 shares of the company’s stock, valued at approximately $6,592,286.40. This trade represents a 47.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 12,500 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The stock was sold at an average price of $71.37, for a total value of $892,125.00. Following the sale, the chief financial officer directly owned 97,994 shares of the company’s stock, valued at $6,993,831.78. This represents a 11.31% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 233,791 shares of company stock worth $15,757,860 over the last ninety days. Corporate insiders own 15.69% of the company’s stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.